Furthermore, lower expression levels of RGS2 in breast cancer samples compared with adjacent tissues were confirmed by four published datasets, TCGA BRAC, GSE36295, GS42568, and GSE54002 (Figure 7H), suggesting that RGS2 might be a candidate tumor suppressor in breast cancer. Here, RGS2 is linked to breast carcinoma.